Goldman Sachs’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.46M | Sell |
303,426
-269,365
| -47% | -$5.73M | ﹤0.01% | 2602 |
|
|
2025
Q1 | $11M | Sell |
572,791
-337,211
| -37% | -$6.5M | ﹤0.01% | 2159 |
|
|
2024
Q4 | $16.2M | Buy |
910,002
+414,647
| +84% | +$7.4M | ﹤0.01% | 1953 |
|
|
2024
Q3 | $10.8M | Buy |
495,355
+41,411
| +9% | +$907K | ﹤0.01% | 2179 |
|
|
2024
Q2 | $3.54M | Sell |
453,944
-226,657
| -33% | -$1.77M | ﹤0.01% | 2858 |
|
|
2024
Q1 | $2.82M | Buy |
680,601
+486,193
| +250% | +$2.01M | ﹤0.01% | 2982 |
|
|
2023
Q4 | $507K | Buy |
194,408
+2,210
| +1% | +$5.77K | ﹤0.01% | 3944 |
|
|
2023
Q3 | $359K | Sell |
192,198
-158,804
| -45% | -$297K | ﹤0.01% | 4028 |
|
|
2023
Q2 | $881K | Sell |
351,002
-89,887
| -20% | -$226K | ﹤0.01% | 3699 |
|
|
2023
Q1 | $772K | Buy |
440,889
+385,378
| +694% | +$674K | ﹤0.01% | 3840 |
|
|
2022
Q4 | $236K | Sell |
55,511
-5,229
| -9% | -$22.2K | ﹤0.01% | 4444 |
|
|
2022
Q3 | $72K | Buy |
60,740
+26,347
| +77% | +$31.2K | ﹤0.01% | 4989 |
|
|
2022
Q2 | $34K | Sell |
34,393
-2,384
| -6% | -$2.36K | ﹤0.01% | 5349 |
|
|
2022
Q1 | $90K | Sell |
36,777
-10,313
| -22% | -$25.2K | ﹤0.01% | 5342 |
|
|
2021
Q4 | $126K | Buy |
47,090
+5,536
| +13% | +$14.8K | ﹤0.01% | 5159 |
|
|
2021
Q3 | $208K | Buy |
41,554
+865
| +2% | +$4.33K | ﹤0.01% | 4847 |
|
|
2021
Q2 | $304K | Sell |
40,689
-45,820
| -53% | -$342K | ﹤0.01% | 4702 |
|
|
2021
Q1 | $508K | Buy |
86,509
+51,700
| +149% | +$304K | ﹤0.01% | 4343 |
|
|
2020
Q4 | $164K | Buy |
+34,809
| New | +$164K | ﹤0.01% | 4340 |
|